scholarly journals Burden changes in caregivers of patients with type 2 diabetes: A longitudinal study

2018 ◽  
Vol 74 (10) ◽  
pp. 2322-2330 ◽  
Author(s):  
M. Suely Alves Costa ◽  
José C. Machado ◽  
M. Graça Pereira
2020 ◽  
Author(s):  
Elena Succurro ◽  
Teresa Vanessa Fiorentino ◽  
Sofia Miceli ◽  
Maria Perticone ◽  
Angela Sciacqua ◽  
...  

<b>Objective</b>: Most, but not all studies suggested that women with type 2 diabetes have higher relative risk (RR) for cardiovascular disease (CVD) than men. More uncertainty exists on whether the RR for CVD is higher in prediabetic women compared to men. <p><b>Research Design and Methods</b>: In a cross-sectional study, in 3540 normal glucose tolerant (NGT), prediabetic, and diabetic adults, we compared the RR for prevalent non-fatal CVD between men and women. In a longitudinal study including 1658 NGT, prediabetic, and diabetic adults, we compared the RR for incident major adverse outcomes, including all-cause death, coronary heart disease, and cerebrovascular disease events after 5.6 years follow-up. </p> <p><b>Results:</b> Women with prediabetes and diabetes exhibited greater relative differences in BMI, waist circumference, blood pressure, total, LDL and HDL cholesterol, triglycerides, fasting glucose, hsCRP, and white blood cell count than men with prediabetes and diabetes when compared with their NGT counterparts. We found a higher RR for prevalent CVD in diabetic women (RR 9.29; 95% CI 4.73-18.25; <i>P</i><0.0001) than in men (RR 4.56; 95% CI 3.07-6.77; <i>P</i><0.0001), but no difference in RR for CVD was observed comparing prediabetic women and men. In the longitudinal study, we found that diabetic, but not prediabetic women have higher RR (RR 5.25; 95% CI 3.22-8.56; <i>P</i><0.0001) of incident major adverse outcomes than their male counterparts (RR 2.72; 95% CI 1.81-4.08; <i>P</i><0.0001).</p> <p><b>Conclusions:</b> This study suggests that diabetic, but not prediabetic, women have higher RR for prevalent and incident major adverse outcomes than men. </p>


Diabetes Care ◽  
2010 ◽  
Vol 33 (11) ◽  
pp. 2383-2389 ◽  
Author(s):  
H. C. Looker ◽  
J. Krakoff ◽  
V. Andre ◽  
K. Kobus ◽  
R. G. Nelson ◽  
...  

2013 ◽  
Vol 15 (12) ◽  
pp. 990-995 ◽  
Author(s):  
Arundhati Dasgupta ◽  
Jasjeet Wasir ◽  
Maria Beloyartseva ◽  
Sandeep Malhotra ◽  
Ambrish Mithal

2001 ◽  
Vol 28 (4) ◽  
pp. 434-438
Author(s):  
Katsuko OKUDA ◽  
Kazuyo TSUSHITA ◽  
Toru IWATSUKA

Author(s):  
De las Nieves López MA ◽  
◽  
Robles Mateos C ◽  
Soria Cano JJ ◽  
Barón Fernandez O ◽  
...  

Background and Methods: Gliflozins are widely prescribed drugs in patients with type 2 diabetes. We pursue to explain abnormal increments in red cell parameters observed in this population, by means of a longitudinal study in 149 patients with a gliflozins exposure period of 12±6 months. Red cell parameters, HbA1c and other variables were recorded. Results: HbA1c fraction decreased (-0.5±1.3, 95% CI: -0.7 to -0.3, p<0.001), while mean hemoglobin (0.5±0.9, 95% CI: 0.3 to 0.6, P<0.001) and hematocrit (1.6±2.6, 95% CI: 1.2 to 2.0, P<0.001) increased. Mean (SD) hematocrit increased 2.7±1.9 in 112 patients, and decreased -1.7±1.5 in 37 (p<0.001 for subgroup differences). The larger increments in PCV were proportional to higher plasma fraction at baseline (p=0.009). Conclusion: Red cell parameters after gliflozins exposure tend to increase and may reach abnormally high thresholds in some patients with type 2 diabetes.


Diabetes Care ◽  
2020 ◽  
Vol 44 (1) ◽  
pp. e12-e14
Author(s):  
António C.-V. Martinho ◽  
Inês P. Marques ◽  
Ana L. Messias ◽  
Torcato Santos ◽  
Maria H. Madeira ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document